One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.

NEW YORK – Alentis Therapeutics on Tuesday announced that it has raised $181.4 million in a series D financing round, and that it will put the funds toward developing antibody-drug conjugates ...

NEW YORK – Neurogene on Monday said after the market closed that it will stop advancing NGN-101 as a treatment for CLN5 Batten disease, a very rare genetic disorder. The New York-based company said it ...

The firm will use the funding to support the Phase I trial of its CAR T-cell therapy, VIPER-101, in lymphoma patients.

Ideaya plans to submit an investigational new drug application next year for IDE034, a B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate.

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

NEW YORK – Canhelp Genomics on Monday said it is collaborating with Mirxes Singapore to provide solid tumor origin identification testing services in Singapore, Malaysia, Thailand, Indonesia, and the ...

A half-dozen hospital systems plan to implement the tool, which combs through patient medical records to identify those ...

The agency reviewed data from the FELIX trial, in which 63 percent of patients achieved a complete remission on the cell therapy at any time point.

Based on early Phase I/II trial data, Tango has decided to end enrollment in a study of TNG908 and focus resources on more promising drugs in its pipeline.

The partners are advancing a pipeline of engineered DNase I therapies designed to work with CAR T cells to kill tumor cells.